|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
Join iWalk for Carcinoid to Support the carcinoid and neuroendocrine community! Without leaving your home, putting on your sneakers, or spending any money, you can make a difference. CFCF can receive up to $10,000 from Novartis Pharmaceuticals Corporation that will enable scientific research that in pursuit of a cure! Click here to start iWalk-ing! |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
Submitted 10/2010
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients. Read our newest survivor stories:
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS From 990
|
|
We are proud to be a BBB accredited charity!
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. | |
|
|
|
|
|
CFCF Launches New Website!
 The Caring for Carcinoid Foundation is pleased to launch a new and improved website! This user-friendly site features a plethora of patient resources, including Patient Education Conference Materials, a Video Gallery, and a section for Newly Diagnosed patients.
We welcome your feedback; check out the new website and contact info@caringforcarcinoid.org with comments and suggestions.
Our website may still be accessed through the address www.caringforcarcinoid.org. Please bear with us as some updates are still being made. |
|
Palo Alto Moonlight Runners Raise over $10,000 to support the CFCF Biobank
 We would like to extend our appreciation for the Team CFCF runners and walkers who participated in the Palo Alto Moonlight Run/Walk as part of our inaugural Stanford Patient Education Weekend.Team CFCF was tremendously successful in raising funds for Stanford Cancer Center's participation in the CFCF Neuroendocrine Tumor Biobank; the team raised over $10,000 in total! A special thanks goes out to Julie Seltzer-Firsty and her husband Wayne Firsty who walked 5k to raise $5k! Click here to support Julie in her quest to cure neuroendocrine tumors.
As stated by Dr. George Fisher, "Tissue is the issue," CFCF is proud to honor Julie and the other participants in the Palo Alto Moonlight Run for raising funds to support critical tissue-banking efforts. Click here to view photos from the event. |
|
Stanford Patient Education Conference Materials
 On September 25, CFCF co-hosted a Patient Education Conference with Stanford Cancer Center for leading specialists in mulitple fields to share the latest in neuroendocrine understanding. Over 125 patients, caregivers, friends, and family members were in attendance.
For those who were not able to join us, we have posted speaker presentations on our website! Click here to view the list of speakers and their slide presentations.
A video recording of the conference will be posted in upcoming weeks, so stay tuned!
|
|
Team CFCF in the Chicago Marathon
 On October 10, CFCF took to the streets of Chicago for our fourth annual Chicago Marathon! This year, Team CFCF raised funds to support Dr. Matthew Meyerson's Carcinoid Cancer Genome Study.
Carcinoid cancer survivor and community advocate, Kari Jones ran her first marathon ever in Chicago. Kari declares "I'm feeling better than I've felt in years and know that my carcinoid is not going to stop me from reaching this goal." To support Kari's amazing feat, click here. Or, click here to read more about Kari and her story. |
|
A Phase I Study Finds Y-90 Therapy Safe for Children and Young Adults
 A phase I study recently published in the Journal of Nuclear Medicine concluded that PRRT with Y-90 is safe in children and young adults. According to investigators, PRRT with Y-90 demonstrated a favorable safety profile in children and young adults with refractory solid tumors that express somatostatin receptors. No dose-limited toxicities were observed. However, the maximum tolerable dose of this therapy varies from patient to patient.
Overall, subjects reported improved quality of life during PRRT with Y-90. Click here to access the abstract of the article entitled Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors.Patients should discuss these results with their doctor. Please call us at 617-848-3977 or visit our Doctor Database for assistance in finding a doctor. |
|
Chemotherapy Combination Effective for Metastatic Pancreatic Neuroendocrine Tumor Patients
 Researchers at the H. Lee Moffit Cancer Center found that metastatic pancreatic neuroendocrine tumor patients had an "exceptionally high and durable response rate" when treated with the combination of capecitabine and temozolomide in front-line chemotherapy. Response, survival, and toxicity rates of this treatment combination were superior to those of streptozocin-based regimens. Although the synergistic relationship between capecitabine and temozolmide is not fully understood, it has demonstrated promising outcomes in metastatic pancreatic neuroendocrine tumor patients. Click here to access the abstract of the article entitled First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas. Patients should discuss these results with their doctor. Please call us at 617-848-3977 or visit our Doctor Database for assistance in finding a doctor. |
|
Advertisement from our Sponsor   | |
|
|
|
